Connecting Some of the DotsRead thru the latest corporate/investor presentation and have the following points would like to create discussion on:
Love the fact they put the "capacity timeline" on the presentation.
Key points here are the "additional sourcing" and outdoor opportunity. AS the CBD (THC for that matter) gain more and more acceptance as a medical product they will be sourcing product (CBD for sure) elsewhere, cause they are going to need it!
If CBD can be sourced cheaper than growing/extracting that is better for the Satipharm revenue stream - I suspect this will be the case in short order with all the capacity coming on stream in North America and other countries as well.
Delivra is the #1 pain releif cream in Canada - interesting. Brand awareness and confidence from those who are "in need" of quality products that work.
Delivra has 7 patents pending (4 registered)...interesting!
Any thoughts ?